Drug Profile


Alternative Names: APC-8015; APC8015F; Autologous PAP-loaded dendritic cell vaccine (APC8015); Prostate cancer vaccine (APC-8015); Provenge

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Dendreon Corporation
  • Class Cancer vaccines; Dendritic cell vaccines; T lymphocyte cell therapies; Tissue extracts
  • Mechanism of Action Immunostimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No
  • Available For Licensing Yes - Prostate cancer

Highest Development Phases

  • Marketed Prostate cancer

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 01 Jun 2015 Dendreon completes a phase II trial in Prostate cancer (Hormone refractory, Late-stage disease) in Austria, France, Netherlands and United Kingdom (NCT01477749)
  • 22 Apr 2015 No recent reports on development identified - Phase-III for Prostate cancer (First-line therapy, Hormone refractory, Metastatic disease) in Canada (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top